Jost B. Jonas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jost B. Jonas has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Liang Xu
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
11 shared publicationsYaxing Wang
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China; and
4 shared publicationsFlorian Rensch
Department of Ophthalmology, Medical Faculty Mannheim, Ruprecht‐Karls‐University of Heidelberg, Mannheim, Germany
3 shared publicationsL Xu
Beijing Institute of Ophthalmology, 17 Hougou Street, Chong Wen Men, 100005 Beijing, China
3 shared publicationsTeodosio Libondi
Department of Ophthalmology, Faculty of Medicine and Surgery, II University of Naples, Naples, Italy
3 shared publicationsYa Xing Wang
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 6 April 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (4) , e320-e326
Neuroprotective effect of intravitreal cell‐based glucagon‐like peptide‐1 production in the optic nerve crush model
: Purpose: To examine the effect of intraocularly produced glucagon‐like peptide‐1 (GLP‐1) on the survival rate of retinal ganglion cells in an optic nerve crush model.Methods: Forty‐one Sprague–Dawley rats were divided into a study group (21 animals) in which 4 beads with 3000 genetically modified cells to produce GLP‐1 were intravitreally implanted into the right eye; a saline control group (n = 12) with intravitreal saline injection; and a GLP‐1 negative bead control group (n = 8) in which 4 beads with 3000 cells without GLP‐1 production were intravitreally implanted. The right optic nerves of all animals were crushed in a standardized manner. After labeling the retinal ganglion cells by injecting 3% fluorogold into the superior colliculus, the animals were sacrificed, and the ganglion cells were counted on retinal flat mounts.Results: The retinal ganglion cell density of the right eyes was significantly higher in the study group (median: 2081 cells/mm2; range: 1182–2953 cells/mm2) than in the GLP‐1 bead negative control group (median: 1328 cells/mm2; range: 1007–2068 cells/mm2; p = 0.002) and than in the saline control group (median: 1777 cells/mm2; range: 1000–2405 cells/mm2; p = 0.07). Correspondingly, the survival rate (ratio of retinal ganglion cell density of right eye/left eye) was significantly higher in the study group (median: 0.72; range: 0.40–1.04) than in the GLP‐1 bead negative control group (median: 0.44; range: 0.36–0.68; p = 0.003) and than in the saline control group (median: 0.56; range: 0.36–0.89; p = 0.03).Conclusion: Glucagon‐like peptide‐1 produced by intravitreally implanted cell beads was associated with a higher survival rate of retinal ganglion cells after an experimental optic nerve crush in rats.
- 6 April 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (4) , e320-e326
Open AccessNeuroprotective effect of intravitreal cell‐based glucagon‐like peptide‐1 production in the optic nerve crush model
: Purpose: To examine the effect of intraocularly produced glucagon‐like peptide‐1 (GLP‐1) on the survival rate of retinal ganglion cells in an optic nerve crush model.Methods: Forty‐one Sprague–Dawley rats were divided into a study group (21 animals) in which 4 beads with 3000 genetically modified cells to produce GLP‐1 were intravitreally implanted into the right eye; a saline control group (n = 12) with intravitreal saline injection; and a GLP‐1 negative bead control group (n = 8) in which 4 beads with 3000 cells without GLP‐1 production were intravitreally implanted. The right optic nerves of all animals were crushed in a standardized manner. After labeling the retinal ganglion cells by injecting 3% fluorogold into the superior colliculus, the animals were sacrificed, and the ganglion cells were counted on retinal flat mounts.Results: The retinal ganglion cell density of the right eyes was significantly higher in the study group (median: 2081 cells/mm2; range: 1182–2953 cells/mm2) than in the GLP‐1 bead negative control group (median: 1328 cells/mm2; range: 1007–2068 cells/mm2; p = 0.002) and than in the saline control group (median: 1777 cells/mm2; range: 1000–2405 cells/mm2; p = 0.07). Correspondingly, the survival rate (ratio of retinal ganglion cell density of right eye/left eye) was significantly higher in the study group (median: 0.72; range: 0.40–1.04) than in the GLP‐1 bead negative control group (median: 0.44; range: 0.36–0.68; p = 0.003) and than in the saline control group (median: 0.56; range: 0.36–0.89; p = 0.03).Conclusion: Glucagon‐like peptide‐1 produced by intravitreally implanted cell beads was associated with a higher survival rate of retinal ganglion cells after an experimental optic nerve crush in rats.
- Open Access
- 29 November 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (8) , e348-e349
Intraocular cell‐based production of glucagon‐like peptide‐1 in the anterior chamber
- 29 November 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (8) , e348-e349
Open AccessIntraocular cell‐based production of glucagon‐like peptide‐1 in the anterior chamber
- 27 August 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (6) , 630-634
Combined intravitreal bevacizumab and triamcinolone in exudative age‐related macular degeneration
Acta Ophthalmol. 2010: 88: 630–634: Purpose: We report on the combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age‐related macular degeneration (AMD).Methods: The clinical interventional case‐series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5 ± 1.8 mono‐injections of bevacizumab (1.5 mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. All patients were re‐examined at 2–3 months after the intervention.Results: Visual acuity improved significantly (p = 0.03) from 0.80 ± 0.40 logMAR prior to the combined injection to 0.65 ± 0.42 logMAR at 3 months after the injection. An improvement of ≥ 1 Snellen line was found in eight subjects, an increase of ≥ 2 lines in five subjects, and an improvement of ≥ 3 lines in two subjects. One patient lost 1 line and one patient lost 3 lines. Central retinal thickness decreased significantly from 272 ± 62 μm to 220 ± 47 μm (p = 0.03). At the 6‐month follow‐up examination, central retinal thickness had increased again to 319 ± 142 μm, which was not significantly (p = 0.30) different from baseline measurements.Conclusions: The combined intravitreal application of bevacizumab and triamcinolone may temporarily be helpful in the treatment of exudative AMD if previous intravitreal bevacizumab mono‐injections have failed to improve vision and reduce macular oedema.
- 27 August 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (6) , 630-634
Combined intravitreal bevacizumab and triamcinolone in exudative age‐related macular degeneration
Acta Ophthalmol. 2010: 88: 630–634: Purpose: We report on the combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age‐related macular degeneration (AMD).Methods: The clinical interventional case‐series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5 ± 1.8 mono‐injections of bevacizumab (1.5 mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. All patients were re‐examined at 2–3 months after the intervention.Results: Visual acuity improved significantly (p = 0.03) from 0.80 ± 0.40 logMAR prior to the combined injection to 0.65 ± 0.42 logMAR at 3 months after the injection. An improvement of ≥ 1 Snellen line was found in eight subjects, an increase of ≥ 2 lines in five subjects, and an improvement of ≥ 3 lines in two subjects. One patient lost 1 line and one patient lost 3 lines. Central retinal thickness decreased significantly from 272 ± 62 μm to 220 ± 47 μm (p = 0.03). At the 6‐month follow‐up examination, central retinal thickness had increased again to 319 ± 142 μm, which was not significantly (p = 0.30) different from baseline measurements.Conclusions: The combined intravitreal application of bevacizumab and triamcinolone may temporarily be helpful in the treatment of exudative AMD if previous intravitreal bevacizumab mono‐injections have failed to improve vision and reduce macular oedema.
- 27 May 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (4) , e131-e132
Intravitreal autologous bone‐marrow‐derived mononuclear cell transplantation
- 27 May 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (4) , e131-e132
Intravitreal autologous bone‐marrow‐derived mononuclear cell transplantation
- Open Access
- 6 April 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (4) , e377-e378
Macular holes and central retinal detachment
- 6 April 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (4) , e377-e378
Open AccessMacular holes and central retinal detachment
- 19 March 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (4) , e375-e377
Clinical assessment of the optic disc at risk of nonarteritic anterior ischaemic optic neuropathy
- 19 March 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (4) , e375-e377
Clinical assessment of the optic disc at risk of nonarteritic anterior ischaemic optic neuropathy
- 19 March 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (1) , e96
Retinal attachment after transconjunctival exocryocoagulation of retinal horse shoe tears
- 19 March 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 89 (1) , e96
Retinal attachment after transconjunctival exocryocoagulation of retinal horse shoe tears
- 1 March 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (2) , e22-e23
Intravitreal bevacizumab for neovascular glaucoma
- 1 March 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (2) , e22-e23
Intravitreal bevacizumab for neovascular glaucoma
- Open Access
- 1 May 2009
- Published by Wiley in Acta Ophthalmologica
- Vol. 87 (3) , 353-354
Femtosecond laser-assisted penetrating re-keratoplasty
- 1 May 2009
- Published by Wiley in Acta Ophthalmologica
- Vol. 87 (3) , 353-354
Open AccessFemtosecond laser-assisted penetrating re-keratoplasty
- 11 March 2009
- Published by Wiley in Acta Ophthalmologica
- Vol. 87 (2) , 235
Follow‐up of glaucomatous eyes with optic disc haemorrhages: the Beijing Eye Study
- 11 March 2009
- Published by Wiley in Acta Ophthalmologica
- Vol. 87 (2) , 235
Follow‐up of glaucomatous eyes with optic disc haemorrhages: the Beijing Eye Study